They further found that integrin αvβ6-blocking antibody monotherapy or combined with a PD-1 antibody, which has entered clinical trials, significantly down-regulates the SOX4 expression, sensitize cancer cells to killing by CD8+ T cells, and reduce the primary tumor burden and lung metastatic burden [151]. Here, SOX4 is linked to neoplasm.